Rheumatoid arthritis (RA) is a systemic autoimmune disease that predominantly affects the
joints. The prevalence of RA varies globally, with generally a higher prevalence in …

Despite widespread clinical use of antimalarial drugs such as hydroxychloroquine and
chloroquine in the treatment of rheumatoid arthritis (RA), systemic lupus erythematosus …

The increased risk of cardiovascular morbidity and mortality in rheumatoid arthritis and gout
has been increasingly acknowledged in past decades, with accumulating evidence that …

Objectives To compare mortality risks in patients with rheumatoid arthritis-associated
interstitial lung disease (RA-ILD) and patients with RA without ILD. Design Matched cohort …

Objectives To investigate efficacy and safety of the Janus kinase-1 inhibitor filgotinib in
patients with active rheumatoid arthritis (RA) with limited or no prior methotrexate (MTX) …

Cardiovascular disease (CVD) is markedly increased in patients with rheumatoid arthritis
partly due to accelerated atherosclerosis from chronic inflammation. Traditional …

Objective To characterise safety of the Janus kinase-1 preferential inhibitor filgotinib in
patients with moderately to severely active rheumatoid arthritis. Methods Data were …

The systemic autoimmune disease rheumatoid arthritis (RA) is characterized by increased
cardiovascular mortality and morbidity and is an independent cardiovascular risk factor …

Rheumatoid arthritis (RA) is a prevalent chronic inflammatory arthritis worldwide,
significantly impacting patients and population health. The disease affects women primarily …

Rheumatoid arthritis (RA) patients have a 50% increased risk of cardiovascular (CV)-related
morbidity and mortality. This excess CV risk is closely linked to RA disease severity and …